

Design and Rationale of the B-lines Lung Ultrasound Guided Emergency Department

Management of Acute Heart Failure (BLUSHED-AHF) Pilot Trial

Short Title

BLUSHED-AHF Design and Rationale

Study Authors' Names, Degrees and Affiliations

Frances M Russell, MD

Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN

Robert R Ehrman, MD

Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI

Robinson Ferre, MD

Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN

Luna Gargani, MD

Institute of Clinical Physiology, National Research Council, Pisa, Italy

Vicki Noble, MD

Department of Emergency Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH

Jordan Rupp, MD

Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN

Sean P. Collins, MD, MS

Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN

Benton Hunter, MD

Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN

Kathleen A. Lane, MS

Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN

Phillip Levy, MD, MPH

Department of Emergency Medicine and Integrative Biosciences Center, Wayne State University, Detroit, MI

Xiaochun Li, PhD

Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN

Christopher O'Connor, MD

Division of Cardiology, INOVA Heart and Vascular Institute, Falls Church, VA

Peter S. Pang, MD, MS

Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis EMS, Indianapolis, IN

Corresponding Author

Peter S. Pang, MD, MS

Indiana University School of Medicine

Department of Emergency Medicine

720 Eskenazi Ave, Fifth Third Faculty Office Building, 3rd Floor Emergency Medicine Office

Indianapolis, IN 46202

ppang@iu.edu

Phone: (317) 880-3900

Fax: (317) 880-0545

Total Word Count: 6314

Journal Subject Terms: Heart failure, Ultrasound, Treatment, Quality and Outcomes

Abstract**Background**

Medical treatment for acute heart failure (AHF) has not changed substantially over the last four decades. Emergency department (ED)-based evidence for treatment is limited. Outcomes remain poor, with a 25% mortality or re-admission rate within 30 days post-discharge. Targeting pulmonary congestion, which can be objectively assessed using lung ultrasound (LUS), may be associated with improved outcomes.

Methods

BLUSHED-AHF is a multicenter, randomized, pilot trial designed to test whether a strategy of care that utilizes a LUS-driven treatment protocol outperforms usual care for reducing pulmonary congestion in the ED. We will randomize 130 ED patients with AHF across 5 sites to: a) a structured treatment strategy guided by LUS vs. b) a structured treatment strategy guided by usual care. LUS-guided care will continue until there are ≤ 15 B-lines on LUS or 6 hours post enrollment. The primary outcome is the proportion of patients with B-lines ≤ 15 at the

conclusion of 6 hours of management. Patients will continue to undergo serial LUS exams during hospitalization, to better understand the time course of pulmonary congestion. Follow up will occur through 90 days, exploring days-alive-and-out-of-hospital between the two arms. The study is registered on ClinicalTrials.gov (NCT03136198).

In conclusion, if successful, this pilot study will inform future, larger trial design on LUS driven therapy aimed at guiding treatment and improving outcomes in patients with AHF.

36 Introduction

37 Acute heart failure (AHF) is a major public health burden ¹⁻⁴. Approximately 6 million
38 Americans have chronic HF, and over 870,000 people are newly diagnosed annually ¹. In 2013,
39 over 30 billion dollars were spent on HF alone, with the majority of these costs due to AHF
40 hospitalizations ⁵. For patients aged 65 years and older, HF is the most common reason for
41 hospitalization ⁶. Within 30 days of hospital discharge, 25% of patients will be dead or re-
42 hospitalized ^{7, 8}.

43 Pulmonary congestion is the primary reason that patients with HF seek emergency care ¹,
44 ^{9, 10}. Decongestion is associated with improved outcomes ^{11, 12}. Despite this, many patients
45 remain congested at time of discharge. ^{10, 11, 13, 14}. This may be due to continued reliance on
46 traditional approaches to congestion assessment (i.e. signs and symptoms of HF), which lack
47 sensitivity and have poor inter-rater reliability ^{10, 13, 15, 16}.

48 Because pulmonary decongestion is a vital treatment goal, a more reliable method of
49 assessment, able to be utilized by a broad range of practitioners, is needed. B-line assessment on
50 lung ultrasound (LUS) is an objective, easy-to-learn, quantitative measure of pulmonary
51 congestion. ¹⁶⁻²⁰ Assessment for B-lines outperforms physical examination, chest radiography,
52 and brain natriuretic peptide (BNP) in the diagnosis of AHF ²¹. B-lines are a dynamic marker of
53 pulmonary congestion that clear in response to treatment, though studies have been small ²²⁻²⁵.
54 Persistence of B-lines after hospital discharge in patients with AHF is associated with a worse
55 prognosis, including a greater than five-fold risk of hospital re-admission and mortality ²⁶⁻²⁸.

56 The B-lines Lung Ultrasound Guided Emergency Department Management of Acute
57 Heart Failure (BLUSHED-AHF) pilot trial is an NHLBI funded study designed to test whether a
58 LUS-guided protocol, compared to structured usual care, will lead to more rapid resolution of

pulmonary congestion. We hypothesize that a LUS-driven protocol for ED AHF management will be feasible and will lead to a clinically significant reduction in pulmonary congestion (as measured by B-lines) during the first 6 hours of management. We chose 6 hours to demonstrate this proof-of-concept study of targeting B-lines. In addition, at the time of hospital discharge, we hypothesize patients with persistent B-lines will have worse outcomes. This pilot trial will inform a definitive outcomes study targeting B-lines both in the ED and during hospitalization.

Methods

Study Design and Population

BLUSHED-AHF is multi-center, prospective, randomized control trial. One hundred and thirty patients will be enrolled from 5 EDs, in the United States. Eligibility criteria are listed in Table 1.

Patients fulfilling enrollment criteria will be included after written informed consent. This study has been approved by the Institutional Review Board at all study sites and registered on ClinicalTrials.gov (NCT03136198)

Study Treatment

Enrolled patients will be randomized in a 1:1 fashion to LUS-guided strategy-of-care or structured usual care. Randomization will occur using the REDCap randomization module. Randomization block sizes of 2, 4, and 6 will be used, and stratified by site. The data coordinating center will continuously monitor the recruitment until the targeted sample size is reached.

After initial ED evaluation and randomization, which includes a baseline screening LUS exam and a baseline clinical assessment, patients will have two additional assessments during the initial 6 hours of the protocol (Figure 1).

The first assessment will occur 2-4 hours after enrollment (T1). The second assessment will occur 2-4 hours after the first assessment (T2), or prior to ED disposition for patients discharged from the ED. If a patient is admitted to the hospital or an observation unit the second assessment (T2) will occur at this location. These additional assessments will include both a LUS performed by the study team and a clinical assessment performed by the treating physician.

Clinical Assessment

Treating clinicians in both arms will be asked a series of standardized questions, listed in Table 2, to determine whether their patient's congestion has improved, and what, if any, methods of assessment were used to derive their determination.

Structured usual care

For patients randomized to structured usual care, the treating team will be blinded to LUS assessments. Treatment decisions in the usual care arm will be guided solely by clinical re-assessment. If the treating clinician feels that further treatment is indicated, then care will continue based on the treatment protocol, Figure 1. If the treating clinician deems that the patient has achieved adequate decongestion and no further treatment is indicated, then the treatment algorithm will be halted; however, LUS assessments will continue per protocol.

ED LUS-guided strategy-of-care

Patients randomized to the LUS-guided strategy-of-care arm will have the aforementioned clinical assessment and LUS exam performed. Clinicians in the LUS arm will be instructed to administer further treatment as outlined in Figure 1, until there is a decrease in B-lines on LUS to ≤ 15 , 6 hours of care has been delivered, or the patient has been discharged. Safety guidelines, such as significant drop in blood pressure or very brisk diuresis, are highlighted for the investigators to consider when re-dosing medications per protocol. While we will collect treating clinicians' clinical assessments, the LUS arm treatment protocol is based solely on the persistence of B-lines on LUS. Therefore, if the LUS shows ≤ 15 B-lines the treatment algorithm will be stopped. In contrast, if the LUS shows >15 B-lines, algorithm guided treatment continues based on Figure 1.

During Hospitalization

Throughout hospitalization patients will have serial LUS and physical exam assessments (taken from the medical record), (see Figure 2) regardless of treatment arm. Treating clinicians will be blinded to LUS assessments performed. These follow-up assessments will inform future studies and help determine if ongoing LUS monitoring throughout hospitalization provides meaningful clinical information regarding pulmonary congestion.

Patients will be followed throughout their ED stay, hospital admission, and for 90-days after hospital discharge (Figure 2). We will call patients at both 30 and 90 days post-discharge to assess vital status, unscheduled healthcare visits and re-hospitalization.

LUS Protocol

Machine settings

All enrolled patients will have serial LUS examinations performed using Zonare ZS3 or Z One Pro (Mindray, Mountain View, CA) or Sonosite MTurbo (FUJIFilm Sonosite, Bothell, WA) ultrasound machines with the curvilinear transducer. Ultrasound machine settings will be standardized: depth of 18 centimeters, clip length 6 seconds, and tissue harmonics and multi-beam former turned off. The gain will be adjusted to the individual patient so that the rib shadows appear black and the pleural line with lung sliding are distinct.

Image Acquisition

As patient positioning can affect B-line counts²⁹, all patients will be scanned in a semi-upright position, with the head of the bed at 45 degrees. We will follow previously published LUS scanning protocols¹⁶ utilizing an 8-zone approach, see Figure 3. Videos will be acquired with the probe in a transverse orientation, with the probe indicator facing the patient's right side and the probe face parallel to the adjacent ribs. Two additional videos, one on each side of the chest, will be acquired in the mid-axillary line at the caudal portion of the chest to assess for the presence and size of a pleural effusion.

In addition to the initial LUS examination, up to two additional LUS studies will be performed within 6 hours of enrollment, if the patient remains in the ED. Repeat LUS examinations will be performed daily until discharge or hospital day 7, whichever comes first.

Sonographers and Pre-enrollment Training

Sonographers will range in experience level from novice to expert and will include research associates, postgraduate year (PGY) 1-3 emergency medicine residents, emergency ultrasound fellowship trained faculty, and non-ultrasound trained emergency medicine faculty.

Research associates will be included in those that perform and interpret LUS exams because LUS images are easy to acquire and interpret^{16,30}, and a tool non-physicians are able to utilize³¹. To ensure uniformity and reliability of LUS examinations, all sonographers will complete a standardized ultrasound training course. This will include: 1) a 2-hour training session led by the ultrasound site principal investigator consisting of didactics and image review to practice counting B-lines; and 2) proctored hands-on scanning of patients with pulmonary congestion. To be deemed proficient, sonographers must obtain ≥ 25 LUS videos that have been reviewed by the ultrasound site principal investigator and have achieved an intraclass correlation >0.7 . Over 90% of the LUS videos will have to have B-lines. Twenty percent of these pre-study images will then be reviewed by the LUS Core Lab.

Quantifying B-lines

B-lines are vertical echogenic artifacts that originate from the pleural line, move with respiration and extend to the bottom of the ultrasound screen^{16,17}. In patients with more severe pulmonary edema, B-lines may fuse together.

The total B-line count will be determined by summing the number of B-lines in each of the 8 zones, while the probe is placed in a transverse orientation, to maximize the amount of examined pleura. Each zone is given a B-line score of 0-20 based on the number of B-lines counted in one respiratory cycle across the entire visualized scanning field. To quantify the number of B-lines visualized in each zone, the intercostal space with the greatest number of B-lines within each zone will be used for scoring. Discrete, narrow B-lines will be counted individually. For those that are wide or fused together, the score will be determined by multiplying the percentage of the intercostal space filled with confluent B-lines by 20, thereby

giving a maximum total count of 20 B-lines per individual zone (i.e. if 50% of the screen is filled with confluent B-lines, that will yield a score of $0.5 \times 20 = 10$ B-lines for that zone), see Figure 4.

If, within a single zone, only a pleural effusion is seen but no lung is visualized, a B-line count of 0 will be assigned. If both lung and a pleural effusion are seen in the same intercostal space, then sonographers will count the number of B-lines visualized, as described above. The presence of pleural effusions will be assessed in each hemithorax in zone 4, with the probe held in a coronal plane with the indicator pointed towards the patient's axilla. Pleural effusions will be graded as small, moderate or large.

B-lines will be counted upon completion of LUS exam by the sonographer who obtained the images. Findings will be recorded on a standardized data collection form. Individual zones and a composite B-line score will be recorded.

Core Lab

A Core Lab, consisting of two independent physicians with expertise in LUS, but not associated with one of the study sites, will individually review all images to assess for inter-observer agreement. They will be blinded to study arm, patient information, sonographer interpretation, study site, and the interpretation of the other expert reviewer. Only de-identified images from all study sites will be sent to the Core Lab. Core Lab interpretation will be recorded on a standardized data collection form.

Laboratory Testing

Patients will have labs collected at baseline (while the patient is in the ED), and on hospital day 7 or day of discharge, whichever comes first. Standard venipuncture techniques or other standard blood collection methods will be used in accordance with institutional standards. Laboratory testing will be analyzed by the clinical lab at each respective institution for chemistry and hemoglobin/hematocrit values. Amino-terminal pro B-type natriuretic peptide (NTproBNP) and high-sensitivity (5th generation) troponin T (hsTnT) (Roche Diagnostics, Indianapolis, IN) will be drawn within 6 hours of randomization as well as prior to discharge for study purposes and will be analyzed centrally.

Endpoints

The primary endpoint is the number of patients with ≤ 15 B-lines on LUS at 6 hours after enrollment. Additionally, we will assess the exploratory endpoints listed in Table 3. Using these endpoints we will be able to collect vital data on the ability of LUS to guide AHF management through assessment of dynamic changes, and compare LUS to clinical assessment alone. In addition, we will further examine the prognostic value of LUS B-lines, in comparison to traditional assessments, including a preliminary determination of what B-line count warrants de-escalation of care, and determining when patients are appropriate for discharge. Importantly, assessment of B-lines during hospitalization combined with treatment will inform future study design. As a pilot trial, we have focused on the ED and early phase of management. Future studies may require LUS guidance throughout hospitalization.

Safety Measures

Mortality, unscheduled healthcare visits and re-hospitalization through 90 days will be assessed for safety as well as efficacy signals. Hypotension and acute kidney injury within the first 12 hours of therapy will also be assessed as safety endpoints. A systolic blood pressure that drops below 100 mm Hg at any time or if a patient develops evidence of clinical hypoperfusion (i.e. weakness, dizziness, etc) despite a systolic blood pressure > 100 mm Hg will be immediately assessed and treated as needed. An independent data safety and monitoring board will meet throughout the duration of the study and will oversee patient safety.

Statistical Considerations

The primary hypothesis is that a higher proportion of LUS guided patients will be decongested, defined as LUS B-lines ≤ 15 , than usual care patients at 6 hours after enrollment. Our preliminary data suggest that 25% of patients in the usual care arm will have ≤ 15 B lines at the conclusion of ED AHF management. With 59 patients in each of the two arms, we will have 81% power to detect an effect size of 2 (i.e. 25% in the usual care versus 50% in the LUS-guided strategy), where the type I error rate is set at 0.05 (two-sided). Considering a conservative 10% drop-out rate, we will need a total of 130 subjects. We will perform two types of analysis, intent-to-treat and per-protocol. The Full Analysis Set (FAS) will include all randomized patients, which will be used in the intent-to-treat analysis where patients will be analyzed by the group to which they were randomized. Analyses in the FAS will constitute the main efficacy results for the primary and secondary study efficacy endpoints. The per-protocol analysis will be performed using the Per-Protocol Set (PPS), a subset of the FAS excluding patients with major protocol violations. The major protocol violations that will result in exclusion from the FAS will be identified prior to unblinding the treatment assignments for final analysis. Patients will be

analyzed in the treatment group to which they were randomized. Such results will complement the primary efficacy analyses in the FAS.

Unless stated otherwise, two-sided p values < 0.05 will be considered statistically significant, without adjustment of multiple comparisons. Statistical tables and listings and analyses will be produced using SAS® release 9.4 or later (SAS Institute, Inc, Cary, NC, USA) or other validated statistical software.

Analysis of the Primary Efficacy Endpoint:

The comparison of binary endpoints (B-lines ≤ 15) will be performed using Chi-square or Fishers exact test, as appropriate. Potential covariates will also be considered in a logistic regression setting to improve precision, which includes baseline co-morbidities, baseline medications (in particular, guideline recommended therapies), in-hospital medications, baseline renal function, serum sodium, natriuretic peptide levels, troponin levels, renal function, baseline blood pressure, and discharge medications. Variables such as physical exam, other vital signs, and hemoconcentration may also be included. For NT-proBNP, a percent change greater than 30% and its association with the primary endpoint will be analyzed. This is based on previous work suggesting a 30% change was a key discriminatory threshold for mortality³³⁻³⁵. For hemoconcentration, any increase in either hematocrit and hemoglobin during hospitalization will be considered positive³⁶. These covariates are known markers of risk and are standard of care assessments for the vast majority of AHF admissions. Covariates with univariate significance will be included together with the treatment indicator in a logistic regression model. We will limit the number of covariates (including treatment indicator) such that there are at least 10 events per covariate.

262

263 *Analysis of the Exploratory Endpoints*

264 Days alive and out of hospital (DAOOH) will be compared using t-test or Wilcoxon rank-
265 sum test, as appropriate. Alternatively, we will treat DAOOH as an ordinal outcome and use the
266 proportional odds (PO) regression model to compare the two arms. The PO regression allows for
267 adjustment of baseline covariates to enhance power.

268 We will examine the distribution of B-lines measurements stratified by pre-specified
269 outcomes. Both absolute number and relative change will be evaluated. Receiver operating
270 characteristic (ROC) curves will be plotted together and area under the curve (AUC) will be
271 calculated to understand the prediction performance of B-line measurement. Sensitivity,
272 specificity, positive and negative predictive values will be computed at a number of thresholds of
273 B-line measurements to understand the trade-off between false positive and false negative.
274 Confidence intervals of statistical measures will be constructed using the bootstrap method.³⁷
275 Although 15 B-lines have been previously identified as a valid threshold, an alternative number
276 may be more useful in the ED setting.

277 For reproducibility analysis, generalized linear mixed-effects models will be fitted to
278 estimate the inter- and intra-observer variability, where both patients and observers are treated as
279 random effects.

280 We will compare parameters used to identify congestion, including B-line measurements
281 and other markers, such as physical exam, NTproBNP, eGFR, and hemoglobin/hematocrit.
282 Bootstrap method will be used for the comparison to account for correlations between the
283 markers and the B-line measurements. We will consider two strategies, logistic regressions and a

tree-based method, to explore potential multivariate models for the prediction of 30 or 90-day outcomes.

Models will be compared using the net reclassification rate^{38,39}. Statistical inference of the comparison will be performed using the bootstrap method.

Discussion

Decongestion is a fundamental goal of AHF management. Failure to adequately decongest is associated with worse outcomes. Despite its importance, a universal, robust, well-validated method to assess and grade congestion with high inter-rater reliability does not exist.¹³ Traditional methods, such as body weight measurement, fluid balance, and physical exam continue to form the foundation of congestion assessment. Determination of whether alternative methods of congestion assessment, such as LUS, perform better than accurately performed traditional assessment is of critical importance.

The B-lines Lung Ultrasound Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF) Pilot Trial is designed to answer whether targeting B-lines – a marker of pulmonary congestion – leads to more rapid resolution of pulmonary congestion compared to usual care during the ED phase of management. Importantly, both arms will follow the same treatment protocol. One limitation of this study design is the absence of a true ‘usual care’ arm, where there is no standard treatment protocol. However, if LUS proved superior to usual care, it could be fairly argued that LUS is less important than a standard treatment protocol. As this is a pilot-trial, should targeting B-lines prove successful, a larger 3-arm study will be considered in future studies.

Another limitation is that ultrasound is highly operator-dependent, which could alter the sonographers acquisition and interpretation of LUS B-lines. Nevertheless, ultrasound assessment of B-lines is one of the easier ultrasound examinations to perform, and we designed a rigorous pre

enrollment training program where each sonographer needs to achieve an intraclass correlation >0.7 with an expert. This is an effort to decrease variation in B-line quantification between different sonographers.

Additionally, there is no way to blind the clinical status of the patient to the study team performing LUS assessments. Despite this, all of the LUS performed for the study will be reviewed by a Core Lab of two expert sonographers, blinded to study arm, to assess for agreement.

A recent systematic review on the value of LUS B-lines in assessment of pulmonary congestion in patients with HF highlighted several gaps in the current literature⁴⁰. First, there are no objective, qualitative data on what represents adequate B-line reduction in response to standardized AHF treatment. Similarly, the time course of B-line resolution, based on treatment of different HF phenotypes, is unclear. The current body of literature in this area is limited, and lacks standardization with heterogeneity in imaging protocols, HF treatment and quantification of B-lines⁴⁰. The BLUSHED-AHF pilot trial will provide further insight into each of these questions. Other methods of decongestion assessment may also be valuable, such as hemoconcentration or changes in natriuretic peptide levels, which we will analyze these as well. These data will help inform future studies considering LUS as a standalone tool or as part of a congestion score.

Conclusions

Pulmonary decongestion is a crucial therapeutic goal in AHF. BLUSHED-AHF will test a novel use of LUS to guide AHF management in the ED. This study will assess the incremental value of LUS compared to clinical assessment alone. If successful, this pilot study will inform future trials on LUS-driven therapy aimed at guiding acute treatment, and informing disposition decisions in patients with AHF.

335 Acknowledgements

336 This work is supported through a National Institutes of Health (NIH) grant
337 (1R34HL136986-01). In-kind support for the biomarker assays were generously provided by
338 Roche Diagnostics.

339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357

350 **References**

- 351 1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de
352 Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE,
353 Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER,
354 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L,
355 Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN,
356 Virani SS, Woo D, Yeh RW and Turner MB. Heart Disease and Stroke Statistics-2016 Update:
357 A Report From the American Heart Association. *Circulation*. 2015.
- 358 2. Blehar DJ, Dickman E and Gaspari R. Identification of congestive heart failure via
359 respiratory variation of inferior vena cava diameter. *Am J Emerg Med*. 2009;27:71-5.
- 360 3. Adams KF, Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT,
361 Berkowitz RL, Galvao M and Horton DP. Characteristics and outcomes of patients
362 hospitalized for heart failure in the United States: rationale, design, and preliminary
363 observations from the first 100,000 cases in the Acute Decompensated Heart Failure
364 National Registry (ADHERE). *American heart journal*. 2005;149:209-16.
- 365 4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC,
366 Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride
367 PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ
368 and Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive
369 Summary: A Report of the American College of Cardiology Foundation/American Heart
370 Association Task Force on Practice Guidelines. *Circulation*. 2013.
- 371 5. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis
372 JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG, on behalf of
373 the American Heart Association Advocacy Coordinating Committee CoAT, Vascular Biology
374 CoCR, Intervention CoCCCoE and Pr. Forecasting the Impact of Heart Failure in the United
375 States: A Policy Statement From the American Heart Association. *Circulation Heart failure*.
376 2013.
- 377 6. Jencks SF, Williams MV and Coleman EA. Rehospitalizations among patients in the
378 Medicare fee-for-service program. *The New England journal of medicine*. 2009;360:1418-
379 28.
- 380 7. Eapen ZJ, Liang L, Fonarow GC, Heidenreich PA, Curtis LH, Peterson ED and
381 Hernandez AF. Validated, electronic health record deployable prediction models for
382 assessing patient risk of 30-day rehospitalization and mortality in older heart failure
383 patients. *JACC Heart failure*. 2013;1:245-51.
- 384 8. Joynt KE, Orav EJ and Jha AK. Thirty-day readmission rates for Medicare
385 beneficiaries by race and site of care. *JAMA : the journal of the American Medical Association*.
386 2011;305:675-81.
- 387 9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC,
388 Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride
389 PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ
390 and Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report
391 of the American College of Cardiology Foundation/American Heart Association Task Force
392 on Practice Guidelines. *Circulation*. 2013.

10. Gheorghiade M, Filippatos G, De Luca L and Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. *The American journal of medicine*. 2006;119:S3-S10.
11. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA and Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. *Am Heart J*. 2000;140:840-7.
12. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC, Jr., Grinfeld L, Udelson JE, Zannad F, Gheorghiade M and Investigators ET. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. *Eur Heart J*. 2013;34:835-43.
13. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of C and European Society of Intensive Care M. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. *Eur J Heart Fail*. 2010;12:423-33.
14. Testani JM, Chen J, McCauley BD, Kimmel SE and Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. *Circulation*. 2010;122:265-72.
15. Wang CS, FitzGerald JM, Schulzer M, Mak E and Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? *JAMA : the journal of the American Medical Association*. 2005;294:1944-56.
16. Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitzkreutz R, Seibel A, Neri L, Storti E and Petrovic T. International evidence-based recommendations for point-of-care lung ultrasound. *Intensive Care Med*. 2012;38:577-91.
17. Picano E, Frassi F, Agricola E, Gligorova S, Gargani L and Mottola G. Ultrasound lung comets: a clinically useful sign of extravascular lung water. *J Am Soc Echocardiogr*. 2006;19:356-63.
18. Agricola E, Bove T, Oppizzi M, Marino G, Zangrillo A, Margonato A and Picano E. "Ultrasound comet-tail images": a marker of pulmonary edema: a comparative study with wedge pressure and extravascular lung water. *Chest*. 2005;127:1690-5.
19. Gargani L, Frassi F, Soldati G, Tesorio P, Gheorghiade M and Picano E. Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: a comparison with natriuretic peptides. *Eur J Heart Fail*. 2008;10:70-7.
20. Jambrik Z, Monti S, Coppola V, Agricola E, Mottola G, Miniati M and Picano E. Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water. *Am J Cardiol*. 2004;93:1265-70.
21. Martindale JL. Diagnosing Acute Heart Failure in the Emergency Department. *Acad Emerg Med*. 2016.

22. Noble VE, Murray AF, Capp R, Sylvia-Reardon MH, Steele DJ and Liteplo A. Ultrasound assessment for extravascular lung water in patients undergoing hemodialysis. Time course for resolution. *Chest*. 2009;135:1433-9.
23. Volpicelli G, Caramello V, Cardinale L, Mussa A, Bar F and Frascisco MF. Bedside ultrasound of the lung for the monitoring of acute decompensated heart failure. *Am J Emerg Med*. 2008;26:585-91.
24. Frassi F, Gargani L, Gligorova S, Ciampi Q, Mottola G and Picano E. Clinical and echocardiographic determinants of ultrasound lung comets. *Eur J Echocardiogr*. 2007;8:474-9.
25. Ohman J, Harjola VP, Karjalainen P and Lassus J. Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. *Eur Heart J Acute Cardiovasc Care*. 2017;2048872617708974.
26. Gargani L, Pang PS, Frassi F, Miglioranza MH, Dini FL, Landi P and Picano E. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. *Cardiovasc Ultrasound*. 2015;13:40.
27. Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto I, Zannad F and Girerd N. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. *Eur J Heart Fail*. 2015;17:1172-81.
28. Cogliati C, Casazza G, Ceriani E, Torzillo D, Furlotti S, Bossi I, Vago T, Costantino G and Montano N. Lung ultrasound and short-term prognosis in heart failure patients. *International journal of cardiology*. 2016;218:104-108.
29. Frasure SE, Matilsky DK, Siadecki SD, Platz E, Saul T and Lewiss RE. Impact of patient positioning on lung ultrasound findings in acute heart failure. *Eur Heart J Acute Cardiovasc Care*. 2014.
30. Martindale JL, Noble VE and Liteplo A. Diagnosing pulmonary edema: lung ultrasound versus chest radiography. *European journal of emergency medicine : official journal of the European Society for Emergency Medicine*. 2013;20:356-60.
31. See KC, Ong V, Wong SH, Leanda R, Santos J, Taculod J, Phua J and Teoh CM. Lung ultrasound training: curriculum implementation and learning trajectory among respiratory therapists. *Intensive care medicine*. 2016;42:63-71.
32. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE and Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *J Am Coll Cardiol*. 2015;66:403-69.
33. Bettencourt P, Azevedo A, Pimenta J, Frioies F, Ferreira S and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation*. 2004;110:2168-74.
34. Stienen S, Salah K, Dickhoff C, Carubelli V, Metra M, Magrini L, Di Somma S, Tijssen JP, Pinto YM and Kok WE. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment. *J Card Fail*. 2015.

35. Stienen S, Salah K, Moons AH, Bakx AL, van Pol PE, Schroeder-Tanka JM, Voogel AJ, Keijer JT, Kortz RA, Dickhoff C, Meregalli PG, Tijssen JG, Pinto YM and Kok WE. Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-ProBNP target on the reduction of readmission and Mortality rates. *Am Heart J*. 2014;168:30-6.
36. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR and Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. *J Am Coll Cardiol*. 2013;62:516-24.
37. Efron B and Tibshirani R. *An Introduction to the Bootstrap*. Boca Raton: Chapman & Hall/CRC; 1993.
38. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr. and Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Statistics in medicine*. 2008;27:157-72; discussion 207-12.
39. Pencina MJ, D'Agostino RB, Sr. and Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Statistics in medicine*. 2011;30:11-21.
40. Platz E, Merz AA, Jhund PS, Vazir A, Campbell R and McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. *Eur J Heart Fail*. 2017.

Figures

Figure 1. Study treatment algorithm.

Figure 2. Trial Schematic and patient flow through study

Figure 3. Pictorial representation of the 8-zone scanning protocol.

Figure 4. LUS image of B-lines taken from Right Zone 1. B-line score for this image is 10.

Data Supplements

Supplemental video showing dynamic B-lines during patient inspiration and expiration.

Table 1: Eligibility Criteria	
Inclusion Criteria	Exclusion Criteria
1) Age \geq 21 years	1) Chronic renal dysfunction, including ESRD or $\text{eGFR} < 45 \text{ml//min/1.73m}^2$
2) Presents with shortness of breath at rest or with minimal exertion	2) Shock of any kind. Any requirement for vasopressors or inotropes
3) Clinical diagnosis of AHF and presence of > 15 total bilateral B-lines on initial LUS	3) SBP < 100 or $> 175 \text{mmHg}$
4) History of chronic HF and any one of the following: <ul style="list-style-type: none"> i. Chest radiograph consistent with AHF ii. Jugular venous distension iii. Pulmonary rales on auscultation iv. Lower extremity edema 	4) Need for immediate intubation

	5) Acute Coronary Syndrome (ACS) OR new ST-segment elevation/depression on EKG. (troponin elevation outside of ACS is allowed)
	6) Fever >101.5°F
	7) End stage HF: transplant list, ventricular assist device
	8) Anemia requiring transfusion
	9) Known interstitial lung disease
	10) Suspected acute lung injury or acute respiratory distress syndrome (ARDS)
	11) Pregnant or recently pregnant within the last 6 months

ESRD – end stage renal disease; eGFR – estimated glomerular filtration rate, SBP – systolic blood pressure;

HF – heart failure

Table 2: Clinical Assessment Form

<ol style="list-style-type: none">1. In your clinical opinion, is the patient still volume overloaded?2. If yes, do you think the patient warrants additional treatment now?3. The following questions will be asked of the physician:<ol style="list-style-type: none">a. Did you assess jugular venous pressure (JVP)?<ol style="list-style-type: none">i. If yes, did you measure it?<ol style="list-style-type: none">1. If yes, record height in centimetersb. Did you auscultate the lungs?<ol style="list-style-type: none">i. If yes, did you hear wheezing, rales, other breath sounds<ol style="list-style-type: none">1. If yes for rales, did you assess how high up the lungs?<ol style="list-style-type: none">a. If yes, then record how high upc. Did you listen to the heart?<ol style="list-style-type: none">i. If yes, did you hear any extra heart sounds?<ol style="list-style-type: none">1. If yes, ask what did you hear?d. Did you assess for peripheral edema?<ol style="list-style-type: none">i. If yes, did you grade severity

Table 3: Exploratory Endpoints	
Total DAOOH through 30 and 90 days post-discharge	Association of B-lines at discharge and 30 and 90 day outcomes
Change in biomarkers from presentation to pre-discharge	Association of baseline, discharge, and change with 30 and 90 day outcomes
Time to reach B-lines <15	B lines < 15 at 24 hours and at discharge
Composite of 30-day all-cause mortality, cardiovascular (CV) re-hospitalizations, and CV emergency department (ED) revisits. CV endpoints are defined according to the 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events. ³² Also for same endpoint, but through 90 days.	All Cause readmissions, All cause ED revisits
Change in physical exam findings and body weight from presentation to pre-discharge	Description of ED pharmacologic treatment
Description of hospital based AHF treatment	Inter and intra-observer agreement
Trajectory of B-line clearance	Assess B-line clearance by sub-group/HF phenotype

DAOOH - Days alive and out of hospital

Figure 1: Study Treatment Algorithm




Figure 2. Trial Schematic and patient flow through study




Figure 3. Pictorial representation of the 8-zone scanning protocol.




Figure 4. LUS image of B-lines taken from Right Zone 1. B-line score for this image is 10.

